In the context of HNSCC, C-MYC has been demonstrated to engage directly with the NFE2L2 promoter, leading to the upregulation of Nrf2 expression and subsequently facilitating the malignant characteristics of cancer by altering nucleotide biosynthesis pathways 78. The gene discussed is NFE2L2; the disease is head and neck squamous cell carcinoma.